Tauriga Sciences Inc. (OTC PINK: TAUG), a company engaged in the building of life sciences businesses and technologies, has today announced that it has secured additional working capital from two existing investors. The Company will utilize this additional capital towards its efforts to remain current in its periodic SEC Filings and successfully prosecute its ongoing malpractice lawsuit against its predecessor audit firm: "Tauriga Sciences, Inc. v. Cowan, Gunteski & Co. P.A. et al" (Case No. 3:16-cv-06285-PGS-DEA).

Tauriga's CEO Seth M. Shaw expressed, "The Company continues to realize progress with respect to its most important goals and milestones. Despite recent weakness in its share price, the Company continues to move forward towards the ultimate goals of creating long term shareholder value and a successful future."

ABOUT TAURIGA SCIENCES, INC.

Tauriga Sciences, Inc. (OTC PINK: TAUG) is a fully reporting life sciences company engaged in the development, marketing, distribution and potential licensing of a broad array of products and technologies that may help individuals who are affected by muscle tension. The Company has already identified potential products and technologies of interest and is actively working towards the goal of creating an innovative product line to launch the business activities of ColluMauxil Therapeutics LLC (The Company's previously announced new planned wholly owned subsidiary). The Company believes that one of its most important strengths is its access to and relationships with potentially substantial distribution systems and networks. The Company intends to capitalize on distribution opportunities and will continually update shareholders on such developments. The Company is also prosecuting (as Plaintiff) its ongoing malpract ice lawsuit against its predecessor audit firm, for which it's seeking monetary damages in excess of $4,500,000 USD.